FadrozoleHydrochloride , 98% , 102676-31-3
Synonym(s):
4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)-benzonitrile;Afema;CGS 16949A
CAS NO.：102676-31-3
Empirical Formula: C14H13N3.ClH
Molecular Weight: 259.739
MDL number: MFCD00866239
| Pack Size | Price | Stock | Quantity |
| 25mg | RMB1149.60 | In Stock |
|
| 50mg | RMB2072.00 | In Stock |
|
| 100mg | RMB3668.00 | In Stock |
|
| 250mg | RMB8424.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 231-233℃ |
| storage temp. | room temp |
| solubility | DMSO: >20mg/mL |
| form | powder |
| color | Pale Beige to Pale Yellow |
| Stability: | Hygroscopic |
Description and Uses
Fadrozole hydrochloride is a non-steroidal imidazole derivative launched for the treatment of post-menopausal breast cancer. Fadrozole is a potent and specific aromatase inhibitor with neither androgenic nor estrogenic activities due to its structural novelty. Fadrozole exerts its action by coordinating with the iron of the porphyrin nucleus, presumably through the imidazole moiety. This strong binding competes with the binding of molecular oxygen to iron and reversibly inactivates the enzyme. An excellent clinical response rate has been reported for fadrozole with no significant side effects.
Antineoplastic.
Safety
| Symbol(GHS) |   GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301-H361 |
| Precautionary statements | P202-P264-P270-P280-P301+P310-P405 |
| Hazard Codes | Xn |
| Risk Statements | 63-22 |
| Safety Statements | 36/37 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | 2 |
| RTECS | DI4952500 |
